Day: May 26, 2022

Fanhua Reports First Quarter 2022 Unaudited Financial Results

Fanhua Reports First Quarter 2022 Unaudited Financial Results

GUANGZHOU, China, May 26, 2022 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: FANH), (the “Company” or “Fanhua”), a leading independent financial services provider in China, today announced its unaudited financial results for the first quarter ended March 31, 20221. Financial Highlights for the First Quarter of 2022: (In thousands, except per ADS) 2021Q1(RMB) 2022Q1(RMB) 2022Q1(US$) Change % Total net revenues 1,095,029   686,387   108,275   (37.3 ) Operating income 140,401   20,589   3,248   (85.3 ) Impairment on investment in an affiliate —   (78,277 ) (12,348 ) N/A   Net income (loss) attributable to the Company’s shareholders 138,385   (37,838 ) (5,969 ) N/A   Non-GAAP net income attributable to the Company’s shareholders2 138,385   40,439   6,379   (70.8 ) Basic and diluted net income (loss) per ADS 2.58   (0.70 ) (0.11 ) N/A   Non-GAAP...

Continue reading

Report On Financial Results For The Three Months Ended March 31, 2022

Report On Financial Results For The Three Months Ended March 31, 2022

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) — Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the three months ended March 31, 2022 (the “Consolidated Financial Statements”) and corresponding Management’s Discussion and Analysis (“MD&A”). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange (“TSX-V”) under the symbol UFC. The Company is a reporting issuer in Alberta, British Columbia and Ontario. Urbanfund’s focus is to invest in Canadian real estate and real estate related projects with a focus on a mix of both residential and commercial properties. The Company’s assets are located in Toronto, Brampton, Belleville,...

Continue reading

StorageVault Announces Results of Annual General and Special Shareholders Meeting

StorageVault Announces Results of Annual General and Special Shareholders Meeting

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault”) (SVI-TSX) is pleased to announce the results of the annual general and special meeting of the shareholders of StorageVault held on May 26, 2022 (the “Meeting”). A total of 264 shareholders holding an aggregate of 270,914,366 common shares of the Corporation were represented at the Meeting in person or by proxy, representing approximately 71.540% of the total votes attached to all issued and outstanding common shares of the Corporation as of the record date on April 18, 2022. All matters put forth at the Meeting were approved, including the appointment of MNP LLP, Chartered Accountants, as auditors of the Corporation for the ensuing year, the approval of the amended stock option plan of the Corporation and the approval of the amended equity incentive...

Continue reading

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies showing the potential for broad activity across tumors driven by MAPK pathway mutations including: KRAS-G12C, KRAS-G12D, KRAS-G12S, KRAS-G12V, NRAS-Q61R, and BRAF-V600E IMM-1-104 IND expected in Q3 2022; Enrollment of the first patient in Phase 1 testing expected in Q4 2022  CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today reported data in two preclinical abstracts at the 2022 ASCO Annual Meeting highlighting the pan-KRAS/NRAS activity of IMM-1-104....

Continue reading

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

– Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma – – Long-Term Follow-up Data from NCI-Sponsored Phase 2 Study of Nirogacestat in Patients with Progressing Desmoid Tumors Also to be Presented – STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced initial clinical data from the Phase 1/2 study evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with BLENREP (belantamab mafodotin-blmf), GSK plc’s (LSE/NYSE: GSK) antibody drug conjugate...

Continue reading

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022

Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve ORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to historical ORR of 66% and CR of 20% for ibrutinib monotherapy Data from p53-mutated MCL and CLL patients show encouraging response rates in sub-group analyses. Landmark PFS was over 80% at 15 months for MCL and 100% at 36 months for CLL in p53-mutated patients treated with zilovertamab plus ibrutinib The combination of zilovertamab and ibrutinib continued to be well tolerated, with an adverse event profile consistent or improved compared with historical data for ibrutinib monotherapy SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT),...

Continue reading

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck cancers NEW YORK and VIENNA, Austria, May 26, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that complete HB-200 Phase 1 results (NCT04180215) for single-vector HB-201 and alternating 2-vector HB-202/HB-201 in patients with advanced Human Papillomavirus 16-positive (HPV16+) cancers, including the recommended Phase 2...

Continue reading

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on expanded development of zotatifin in investor call on June 5th at 7 p.m. ET / 6 p.m. CT SAN DIEGO and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it will present interim data from its ongoing Phase 1/2 dose escalation and expansion trial of zotatifin in multiple solid tumors in an oral poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, including safety, pharmacokinetics, pharmacodynamics and responses in two expansion cohorts. Zotatifin...

Continue reading

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab), and trial-in-progress updates across the RP1, RP2 and RP3 programs WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022. Details for the presentations are as follows: Data presentation Updated results from the skin cancer cohorts from an ongoing Phase 1/2 multi-cohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE) Session...

Continue reading

Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)

Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)

Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022 Development of biomarker offers the potential of a first in class targeted therapy in renal cancer Company has a registrational path for potential accelerated approval as well as full approval of batiraxcept in 2L+ ccRCC HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated Phase 1b/2 ccRCC data at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 3-7, 2022 in Chicago. The abstract presents the updated response rate, landmark progression-free-survival data, and biomarker data. “We are jubilant about the selection of the poster on...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.